Infliximab for the treatment of adults with psoriasis

  • Technology appraisal guidance
  • TA134
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessment Centre, University of Southampton:

  • Loveman E, Turner D, Hartwell D, et al. Infliximab for the treatment of adults with psoriasis, July 2007.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on infliximab by providing a written statement to the Committee. Organisations listed in I and II have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Schering-Plough

II) Professional/specialist and patient/carer groups:

  • Arthritis and Musculoskeletal Alliance

  • Changing Faces

  • Psoriasis Association

  • Psoriatic Arthropathy Alliance

  • Skin Care Campaign

  • Skinship (UK)

  • Specialised Healthcare Alliance

  • British Association of Dermatologists

  • British Dermatological Nursing Group

  • British Skin Foundation

  • British Society for Rheumatology

  • Community Practitioners' and Health Visitors Association

  • Primary Care Dermatology Society

  • Primary Care Rheumatology Society

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Physicians

  • Royal Pharmaceutical Society

III) Commentator organisations (did not provide written evidence and without the right of appeal):

  • Board of Community Health Councils in Wales

  • British National Formulary

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Medicines and Healthcare products Regulatory Agency (MHRA)

  • National Public Health Service for Wales

  • NHS Confederation

  • NHS Purchasing and Supply Agency

  • NHS Quality Improvement Scotland

  • Scottish Medicines Consortium

  • Serono (efalizumab)

  • Wyeth (etanercept, methotrexate)

  • Roche (acitretin)

  • Novartis (ciclosporin)

  • Wockhardt UK (methotrexate)

  • Mayne Pharma (methotrexate)

  • Bristol Myers Squibb (hydroxycarbamide)

  • Medac (hydroxycarbamide)

  • Cochrane Skin Group (Centre of Evidence-based Dermatology, University of Nottingham)

  • Skin Research Centre, University of Leeds

  • Skin Treatment and Research Trust (START)

  • MRC Clinical Trials Unit

  • National Coordinating Centre for Health Technology Assessment

  • Southampton Health Technology Assessment Centre, University of Southampton

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on infliximab by attending the initial Committee discussion and providing written evidence to the Committee. They are invited to comment on the ACD.

  • Dr Chris Griffiths, nominated by Royal College of Physicians – clinical specialist

  • Professor Jonathan Barker, nominated by the British Association of Dermatologists – clinical specialist

  • Mrs Karina Jackson, nominated by the British Dermatological Nursing Group – clinical specialist

  • Ms Gladys Edwards, nominated by Psoriasis Association – patient expert

  • Mr Ray Jobling, nominated by Psoriasis Association – patient expert